Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Cologne – page 18

639 clinical trials in Cologne, Germany across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Cologne at a glance
639
clinical trials
  • Research sites4
Type of trial
Recruitment status
Quick filters

639 trials in Cologne

Open in trial search

Non-small cell lung cancer

Recruiting

Study of Amivantamab, Lazertinib, and Pemetrexed for Patients with Advanced or Metastatic Solid Tumors, Including EGFR-Mutated Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:Janssen Cilag International

Non-small cell lung cancer

Recruiting

Study of NVL-520 for Patients with Advanced ROS1-Positive Lung Cancer and Other Solid Tumors

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Zidesamtinib
  • Sponsor:Nuvalent Inc.

B-cell type acute leukaemia

Recruiting

Study on the Safety and Effectiveness of AZD0486 and Tocilizumab for Adolescents and Adults with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Tocilizumab
  • Sponsor:AstraZeneca AB

Plasma cell myeloma

Recruiting

Study Comparing Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone with Ciltacabtagene Autoleucel or Stem Cell Transplant for Newly Diagnosed Multiple Myeloma Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Invasive lobular breast carcinoma

Recruiting

Study of Capivasertib and Fulvestrant for Patients with High-Risk Lobular Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Camizestrant
  • Sponsor:GBG Forschungs GmbH

Congenital cystic kidney disease

Recruiting

Study on the Safety and Effects of Tolvaptan for Children with Autosomal Recessive Polycystic Kidney Disease (ARPKD)

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Tolvaptan
  • Sponsor:Otsuka Pharmaceutical Development & Commercialization Inc.

Chronic hepatitis B

Recruiting

Study on the Safety and Efficacy of a Hepatitis B Vaccine with Hepatitis B Surface Antigen (rDNA), MVA-HBVAC, and Mosaic HBcoreAg for Adults with Chronic Hepatitis B

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Mva-Hbvac
  • Sponsor:Klinikum der Universitaet Muenchen AöR

Glioma

Recruiting

Study of Larotrectinib and Drug Combination for Children with Newly Diagnosed High-Grade Glioma with NTRK Fusion

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Carboplatin
  • Sponsor:Nationwide Childrens Hospital

Cholangiocarcinoma

Recruiting

Study on Durvalumab, Cisplatin, and Gemcitabine for Patients with Extrahepatic Cholangiocarcinoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Nephroblastoma

Recruiting

Study Comparing Vincristine, Actinomycin-D, and Doxorubicin with Vincristine, Carboplatin, and Etoposide for Stage IV Childhood Kidney Cancer Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Carboplatin
  • Sponsor:GPOH gGmbH

Glioblastoma

Recruiting

Study of Meclofenamate Sodium and Temozolomide for Patients with Progressive MGMT-Methylated Glioblastoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Meclofenamate Sodium
  • Sponsor:Rheinische Friedrich-Wilhelms-Universitaet Bonn

Plasma cell myeloma

Recruiting

Comparison of belantamab mafodotin, bortezomib and dexamethasone versus daratumumab, bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Belantamab Mafodotin
  • Sponsor:Glaxosmithkline Research & Development Limited

Other cities in Germany

The busiest research cities in the country

All 518 cities in Germany

Clinical research in Cologne

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on advanced cancer treatments, including studies for diffuse large B-cell lymphoma, multiple myeloma, and various solid tumors. Research aims to evaluate new combination therapies and targeted treatments.

  • Lymphoma and Blood Cancers
  • Advanced Breast Cancer
  • Non-Small Cell Lung Cancer

Multiple studies are investigating novel drug combinations and immunotherapy approaches.

02 Autoimmune Conditions

Comprehensive research into autoimmune disorders, with particular focus on Sjögren's Disease and rheumatoid arthritis. Studies evaluate new biological therapies and treatment approaches.

  • Inflammatory Myopathies
  • Primary Sjögren's Disease
  • Rheumatic Diseases

Trials aim to improve disease management and patient outcomes through innovative therapies.

03 Infectious Diseases

Groundbreaking research in infectious disease management, including studies on HIV-1 treatment and drug-resistant infections. Focus on developing new therapeutic approaches and treatment strategies.

  • HIV Treatment Innovation
  • Antimicrobial Resistance
  • Pneumococcal Disease

Studies explore novel treatment regimens and preventive approaches.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.